Fresenius acquires generics drugmaker Akorn, Merck’s biosimilars biz

German healthcare company Fresenius (ETR:FRE) said today that it bought U.S. generic drugmaker Akorn Inc. (NSDQ:AKRX) for $4.75 billion and Merck KGaA’s biosimilars business.

Since chief executive Stephan Sturm took the helm in June, the company has made takeovers a key part of its strategy. Fresenius bought a Spanish hospital chain for 5.8 billion euros in September last year.

The company’s latest acquisitions show an attempt to move into new dosage forms and therapeutic areas for its Kabi unit, which develops generic infusion drugs and blood transfusion supplies.

Get the full story at our sister site, Drug Delivery Business News.

The post Fresenius acquires generics drugmaker Akorn, Merck’s biosimilars biz appeared first on MassDevice.

from MassDevice http://ift.tt/2phAfzJ